Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Grupo Español de Investigación en Cáncer de Ovario
With
PharmaMar
Age
Any age
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients who have received at least one dose of trabectedin - doxorubicin pegylated for recurrent ovarian cancer according to SMPC, between October 28, 2009 and October 31, 2014 and which have not been included in clinical trials where the IMP was trabectedin.
You may not be if
Patients with records unavailable (lost, empty or not recoverable).
Clareo Health | Retrospective Study to Analyze the Efficacy and Safety of Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), According to SmPC
